Diagnostics

medicine

Worldwide Cancer Molecular Diagnostics Industry to 2025 – Personalized Medicine and Pharmacogenomics are Driving Growth

DUBLIN, Dec. 1, 2020 /PRNewswire/ — The “Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. The publisher’s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role

Read More
medicine

Worldwide Cancer Molecular Diagnostics Industry to 2025

DUBLIN, Dec. 1, 2020 /PRNewswire/ — The “Molecular Diagnostics for Cancer – Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025” report has been added to ResearchAndMarkets.com’s offering.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. The publisher’s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges, please enquire further for more information.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview
2.1 Market Participants
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role

Read More
health

Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond

First collaboration of virtual care provider and national laboratory provider features self-collected at-home specimen collection and mental health care support to empower diverse workforces to access health care safely

Clinical encounter also evaluates patients for risk of COVID-19

SECAUCUS, N.J., Oct. 27, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help organizations facilitate virtual (telehealth) access to clinical services for their employees and adult dependents, with emphasis on reducing risks related to preventable chronic diseases.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)
Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

The first-of-its-kind collaboration specifically focuses on helping employers create a highly convenient and safe way for employees to access thorough and guideline driven preventive care and mental health support during the COVID-19 pandemic. Research shows many individuals are reluctant to seek in-person health care due to fear of contracting the SARS-CoV-2 virus, raising the prospect that untreated, preventable conditions will progress to more advanced disease.

“Social distancing and fear of contracting COVID-19 make it difficult for many individuals to access preventive care services from their healthcare providers. At the same time, employers recognize that at-home care, technology enabled options, including preventive care and screening, can be highly effective in enabling prevention and treatment of chronic diseases, supporting better workforce health and lower medical costs,” said Jay G. Wohlgemuth, M.D., Senior Vice President and Chief Medical Officer, and head of the company’s Employer Population Health programs. “Quest Diagnostics and Catapult Health have complementary capabilities that, together, will improve the ability of organizations to support their employees’ health by providing a patient-centric service that meets them where they are during the pandemic and beyond.”

The collaboration pairs insights from Quest’s biometric screenings offered at-home via specimen self-collection, at Quest’s Patient Service Centers, and at the worksite with Catapult Health’s new VirtualCheckup™ solution. The VirtualCheckup includes a video preventive care checkup to allow for confidential analysis and consultation with a nurse practitioner. Each checkup covers personal and family health history, Quest’s lab test and biometric data, prescription drug adherence, depression screening (PHQ-9), and concludes with the creation of a personal action plan to include referral into employer health and benefits programs. The consultation also screens for potential COVID-19 exposure, and individuals identified as at-risk may be directed to COVID-19 diagnostic testing services provided by Quest.

Health plans typically reimburse Catapult’s preventive care checkups as a covered annual preventive checkup, reducing medical costs for employers and the need for employees to visit a doctor for the checkup.

“When people skip doctor visits, the consequences can be grave in terms of poorer long-term outcomes and higher medical costs,” said David Michel, CEO of Catapult Health. “Because they sponsor much of the nation’s healthcare, employers end up absorbing these costs to a great degree. Our unique virtual care model is designed to change that by taking preventive care into employee’s homes, thereby solving for access

Read More
health

Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025

Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), by Indication (Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, and Kidney Cancer) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 26, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913709/?utm_source=GNW

The Global Cancer Diagnostics Market is expected to grow from USD 140,325.96 Million in 2019 to USD 221,237.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.88%.

Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostic Type, the Cancer Diagnostics Market studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.

Based on Indication, the Cancer Diagnostics Market studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.

Based on Geography, the Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and

Read More